ReviewCureus2024
Comparison of Efficacy and Safety of Baloxavir and Oseltamivir in Children With Influenza: A Systematic Review and Meta-Analysis.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Flu in Flux: The Evolving Controversy Over Oseltamivir for Children Who Are Hospitalized.Hospital pediatrics · 2025Article
- A cost-effectiveness analysis of baloxavir marboxil versus oseltamivir for seasonal influenza treatment in China.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis compared the efficacy and safety of baloxavir marboxil and oseltamivir in treating influenza in children. A comprehensive literature search was conducted across multiple databases, identifying five studies (four observational and one randomized controlled trial) with a pooled sample size of 2,261 patients. The analysis revealed that baloxavir marboxil significantly reduced the duration of fever compared to oseltamivir (mean difference: -13.49 hours, 95% CI: -23.75 to -3.24). However, there was no significant difference in the time to resolution of overall influenza symptoms between the two treatments (mean difference: -4.55 hours, 95% CI: -19.48 to 10.37). Safety analysis, though limited by available data, suggested a lower incidence of nausea and vomiting with baloxavir marboxil compared to oseltamivir. Both drugs demonstrated comparable safety profiles for other adverse events. These findings indicate that while both medications remain viable options for managing pediatric influenza, baloxavir marboxil may offer advantages in terms of rapid fever reduction and potentially fewer gastrointestinal side effects. However, the study highlights the need for more robust, large-scale randomized controlled trials focusing exclusively on pediatric populations to strengthen the evidence base. Clinicians should consider individual patient factors, local resistance patterns, and current guidelines when making treatment decisions. Future research should explore combination therapies and their potential to manage severe influenza cases in children and conduct more comprehensive safety assessments in pediatric populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.